Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $4.1M, vs. Street Est of $4.76M

11/10/2021 | 07:31am EST


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
01/19VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis
MT
01/19VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea..
PU
01/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre..
AQ
01/19VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for th..
CI
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,6 M - -
Net income 2021 -72,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,46x
Yield 2021 -
Capitalization 33,7 M 33,7 M -
Capi. / Sales 2021 2,03x
Capi. / Sales 2022 4,45x
Nbr of Employees 106
Free-Float -
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,63 $
Average target price 5,80 $
Spread / Average Target 821%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-38.24%34
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356